Which medications in the drug class Biological Response Modifiers are used in the treatment of Urothelial Tumors of the Renal Pelvis and Ureters?

Updated: Aug 07, 2020
  • Author: Kyle A Richards, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print
Answer

Biological Response Modifiers

These agents modify immune responses, either by enhancing or suppressing it.

BCG intravesical live (Tice BCG)

BCG intravesical contains live, attenuated mycobacteria. It is indicated for prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). Not recommended for stage TaG1 papillary tumors, unless diagnosed as high risk of tumor recurrence.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!